Perfil
Cino Sitia served as the Chief Executive Officer of Postalmarket SpA from 1966 to 1970.
He also worked as a Director at Xeptagen SpA, a Founding Partner at Mida Spa, and a Principal at Cegos Italia SpA. Mr. Sitia earned an undergraduate degree from the University of Genoa in 1957.
Antiguos cargos conocidos de Cino Sitia.
| Empresas | Cargo | Fin |
|---|---|---|
Postalmarket SpA
Postalmarket SpA Apparel/Footwear RetailRetail Trade Operates chain of retailing outlets | Presidente | 01/01/1970 |
Mida Spa
Mida Spa Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Corporate Officer/Principal | - |
Cegos Italia SpA
Cegos Italia SpA Miscellaneous Commercial ServicesCommercial Services Provides professional training and coaching services | Corporate Officer/Principal | - |
Xeptagen SpA
Xeptagen SpA Medical SpecialtiesHealth Technology Engages in the discovery and validation of molecular biomarkers in order to produce diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy | Director/Miembro de la Junta | - |
Formación de Cino Sitia.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Postalmarket SpA
Postalmarket SpA Apparel/Footwear RetailRetail Trade Operates chain of retailing outlets | Retail Trade |
University of Genoa
University of Genoa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mida Spa
Mida Spa Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Cegos Italia SpA
Cegos Italia SpA Miscellaneous Commercial ServicesCommercial Services Provides professional training and coaching services | Commercial Services |
Xeptagen SpA
Xeptagen SpA Medical SpecialtiesHealth Technology Engages in the discovery and validation of molecular biomarkers in order to produce diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy | Health Technology |
- Bolsa de valores
- Insiders
- Cino Sitia
















